SUPERNUS PHARMACEUTICALS, INC. (SUPN) Form 10-Q — Oct 29, 2026
Supernus Pharmaceuticals reported Q3 2026 revenue of $226.8 million, up 18% year over year, and swung to net earnings of $20.9 million ($0.36 basic EPS) from a $45.1 million loss a year ago. Growth was driven by ZURZUVAE collaboration revenue of $41.7 million (+107%), Qelbree sales of $90.8 million (+12%), and record GOCOVRI sales of $42.6 million. The dominant event is the pending merger of equals with Indivior Pharmaceuticals, which stockholders approved on October 15 and which is expected to close November 2, 2026. Each SUPN share will convert into 1.5401 Indivior shares, with the combined company renamed Supernus, Inc.
Key figures
- Eps
- 0.36
- Revenue
- 226771000
- Net Income
- 20913000
- Revenue Yoy
- 18%
- Total Assets
- 1397690000
- Cash Position
- 175884000
- Diluted eps
- 0.35
- Onapgo q3 sales
- 17100000
- Gocovri q3 sales
- 42600000
- Qelbree q3 sales
- 90824000
- Qelbree sales yoy
- 12%
- Indivior term loan
- $650 million
- Nine month revenue
- 653534000
- Shares outstanding
- 58254131
- Impairment q2 apokyn
- 54900000
- Expected closing date
- November 2, 2026
- Marketable securities
- 183575000
- Nine month revenue yoy
- 29%
- Exchange ratio indivior
- 1.5401
- Indivior special dividend
- $1.0 billion
- Zurzuvae collab revenue q3
- 41697000
- Impairment nine month total
- 56460000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.